State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

State Street Corp boosted its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 8.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 104,490 shares of the company’s stock after buying an additional 8,412 shares during the period. State Street Corp owned approximately 0.11% of Gyre Therapeutics worth $1,310,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. FMR LLC purchased a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at approximately $47,000. Charles Schwab Investment Management Inc. increased its holdings in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the last quarter. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the second quarter valued at approximately $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, WINTON GROUP Ltd acquired a new position in Gyre Therapeutics during the second quarter worth $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Insider Activity at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 10,000 shares of company stock worth $118,680 in the last three months. 19.52% of the stock is owned by company insiders.

Gyre Therapeutics Stock Down 0.8 %

Shares of NASDAQ GYRE opened at $12.00 on Friday. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $27.10. The stock has a fifty day simple moving average of $12.60 and a 200-day simple moving average of $12.67.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.